P1195: A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA.

P1195: A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA.

Bibliographic Details
Main Authors:	M. Kalac, C. Tam, M. Goldfinger, Z. Xiao, S. Rajeeve, F. Montanari, J. Kanakry, O. O’Connor, E. Marchi
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847644.74540.4d

Similar Items

Romidepsin in the treatment of cutaneous T-cell lymphoma
by: Jain S, et al.
Published: (2011-04-01)

Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy
by: Loke, J, et al.
Published: (2021)

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
by: Francine Foss, et al.
Published: (2016-03-01)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
by: Cinzia Pellegrini, et al.
Published: (2016-04-01)

Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
by: Francine Foss, et al.
Published: (2017-09-01)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
by: Cesar Gentille, et al.
Published: (2022-07-01)

Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques
by: Adam J. Kleinman, et al.
Published: (2020-12-01)

OGLE-2016-BLG-1195 AO: Lens, Companion to Lens or Source, or None of the Above?
by: Andrew Gould, et al.
Published: (2023-01-01)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
by: Ole S Søgaard, et al.
Published: (2015-09-01)

P1195: A PROSPECTIVE STUDY OF TARGETED SEQUENTIAL IMMUNOTHERAPY. IN PATIENTS WITH RELAPSED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA.
by: Yuelu Guo, et al.
Published: (2023-08-01)

Asimov's biographical encyclopedia of science and technology : the lives and achievements of 1195 great scientists/
by: Asimov, Isaac, 1920-1992
Published: (1972)

Romidepsin controls chronic lymphocytic leukemia in a patient with mycosis fungoides
by: David M. Lemchak, et al.
Published: (2016-11-01)

Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin
by: Nasreddine El Omari, et al.
Published: (2023-08-01)

Synergistic Effect Of Simvastatin And Romidepsin On Gamma-Globin Gene Induction
by: Hussain Habibi, et al.
Published: (2018-08-01)

Simvastatin-romidepsin combination kills bladder cancer cells synergistically
by: Kazuki Okubo, et al.
Published: (2021-09-01)

Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine—A Retrospective Analysis
by: Kamil Wiśniewski, et al.
Published: (2024-03-01)

Simon V of Montfort: The exercise and aims of independent Baronial power at home and on crusade, 1195-1218
by: Lippiatt, G
Published: (2015)

Association of COX-2 Promoter Polymorphisms -765G/C and -1195A/G with Migraine
by: Elahe MOZAFFARI, et al.
Published: (2016-12-01)

Romidepsin Induces G2/M Phase Arrest and Apoptosis in Cholangiocarcinoma Cells
by: Pihong Li MD, et al.
Published: (2020-10-01)

Single romidepsin infusions do not increase HIV expression in persons on ART (A5315)
by: D. McMahon, et al.
Published: (2017-12-01)

Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
by: Shin Yeu Ong, et al.
Published: (2022-07-01)

Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice
by: Yaya Chu, et al.
Published: (2017-09-01)

Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers.
by: Benjamin B Policicchio, et al.
Published: (2016-09-01)

Subcellular storage and release mode of the novel 18F-labeled sympathetic nerve PET tracer LMI1195
by: Xinyu Chen, et al.
Published: (2018-02-01)

Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression
by: M. C. P. Cleophas, et al.
Published: (2019-02-01)

Symptom study app provides real-world data on COVID-19 vaccines
by: Drury, RE, et al.
Published: (2021)

P1201: A REAL-WORLD STUDY OF CHIDAMIDE FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA IN CHINA
by: Xin Wang, et al.
Published: (2023-08-01)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
by: Yuankai Shi, et al.
Published: (2017-03-01)

1195 Discovery of CBO421, a first-in-class drug Fc-conjugate (DFC), targeting CD73 in cancer
by: María Hernández, et al.
Published: (2023-11-01)

First meteor radar observations of tidal oscillations over Jicamarca (11.95° S, 76.87° W)
by: L. Guo, et al.
Published: (2009-06-01)

Different regimens of romidepsin administration for reversion of SIV latency in a rhesus macaque model of complete virus control
by: A. Kleinman, et al.
Published: (2019-07-01)

PB1905: REAL-WORLD EXPERIENCE OF LOW-DOSE VENETOCLAX WITH AZACITIDINE FOR UNFIT AML PATIENTS(≥60Y) WITH LOW LEUKOCYTE COUNT
by: Wenjian Wei, et al.
Published: (2023-08-01)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
by: Anjali Bhatt, et al.
Published: (2022-11-01)

OP 1.8 – 00204 Romidepsin in combination with the BCL-2 antagonist venetoclax synergistically reduce the size of the HIV reservoir
by: Y. Kim, et al.
Published: (2022-12-01)

In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 kick&kill clinical trial
by: Rosás-Umbert, M, et al.
Published: (2020)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
by: Weiping Liu, et al.
Published: (2021-11-01)

Safety and efficacy of azacitidine in myelodysplastic syndromes
by: Carlos E Vigil, et al.
Published: (2010-09-01)

The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitiser in bladder tumours in vivo
by: Paillas, S, et al.
Published: (2020)

Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis
by: Jun Du, et al.
Published: (2021-11-01)